Maintenance therapy for prostate cancer with rising PSA
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests two medications (metformin and a turmeric compound) as a maintenance therapy for men with prostate cancer whose PSA is rising slowly after prior treatment. The goal is to see if these drugs can keep the cancer from growing while you take a break from standard hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have had surgery to remove your prostate or radiation therapy for prostate cancer
- Your PSA is rising (at least two tests in a row, more than a week apart) and the time it takes for your PSA to double is less than 9 months
- Your testosterone level is above 150 ng/dL (normal range)
- You are generally healthy enough to do daily activities (ECOG 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether metformin, added to standard hormone-blocking treatment, can improve outcomes for men with newly diagnosed metastatic hormone-sensitive prostate cancer. It’s meant to test benefits of targeting metabolism in addition to prostate cancer hormone therapy.
This study tests whether curcumin (a supplement made from turmeric) can prevent low-risk prostate cancer from progressing while you stay on active surveillance. If you qualify, you would take curcumin and be monitored closely with regular checkups.
This trial tests if the antifungal drug terbinafine can lower PSA levels in men whose prostate cancer has returned after standard treatments, but who are not yet ready for hormone therapy. It is for men with no distant spread seen on scans except possibly small lymph nodes.
This trial studies whether a structured lifestyle intervention (such as exercise and related behavior changes) can benefit people with metastatic prostate cancer who are currently on hormone treatment. It may help by improving health and functioning while you continue standard cancer therapy.
This trial is testing whether high doses of testosterone can help treat advanced prostate cancer in men who have a specific genetic change (ATM, CDK12, or CHEK2). It is for patients whose cancer has stopped responding to current hormone therapies.
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Hear when a new Castration Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.